<DOC>
	<DOCNO>NCT00044694</DOCNO>
	<brief_summary>This multicenter , randomize , blind , placebo-controlled , short-term , dose-response study examine effect glucose control AC2993 compare placebo patient type 2 diabetes . Patients individual type 2 diabetes treat metformin least 3 month prior screen . Patients whose diabetes management consist diet exercise also eligible study .</brief_summary>
	<brief_title>Evaluation Effect Glucose Control Safety Tolerability AC2993 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Subjects type 2 diabetes Treated diet exercise alone metformin least 3 month prior screen BMI 2745 kg/m^2 HbA1c 7.0 % 8.0 % Treated oral antidiabetic agent metformin within 3 month screen Patients previously treat AC2993 Patients presently treat insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
</DOC>